AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28981385 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab alone
Number of subjects: 0
Study 28981568 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔPOP (pleth variability index) during pneumoperitoneum
Number of subjects: 120
Study 28981568 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔPOP cut-off point of 38%
Number of subjects: 120
Study 28981994 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% transdermal testosterone gels
Number of subjects: 0
Study 28982142 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification of blastocysts with a ≥ 3 h culture interval (Group IV)
Number of subjects: 223
Study 28982142 — intervention group
Group type: COMPARATOR
Intervention: Vitrification of blastocysts with a < 3 h culture interval (Group I)
Number of subjects: 223
Study 28982159 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of hypertension
Number of subjects: 1159
Study 28982159 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for hypertension
Number of subjects: 1159
Study 28982159 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of hypertension
Number of subjects: 1159
Study 28982258 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic biliary drainage combined with a duodenal stent
Number of subjects: 110
Study 28982258 — intervention group
Group type: COMPARATOR
Intervention: EUS-guided biliary drainage
Number of subjects: 110
Study 28982258 — intervention group
Group type: COMPARATOR
Intervention: Metal stents
Number of subjects: 110
Study 28982374 — intervention group
Group type: EXPERIMENTAL
Intervention: High malaria burden (≥ 2 episodes of symptomatic malaria or ≥ 50% of samples LAMP+)
Number of subjects: 282
Study 28982374 — intervention group
Group type: EXPERIMENTAL
Intervention: Low malaria burden (0-1 episodes of symptomatic malaria and < 50% of samples LAMP+)
Number of subjects: 282
Study 28982374 — intervention group
Group type: COMPARATOR
Intervention: No malaria exposure during pregnancy
Number of subjects: 282
Study 28982374 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of placental parasites by any method
Number of subjects: 282
Study 28982495 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy breakfast (contributing to >20% of total daily energy intake)
Number of subjects: 4052
Study 28982495 — intervention group
Group type: COMPARATOR
Intervention: Skipping breakfast (consuming <5% of total daily energy)
Number of subjects: 4052
Study 28982495 — intervention group
Group type: COMPARATOR
Intervention: Low-energy breakfast (contributing between 5% and 20% of total daily energy intake)
Number of subjects: 4052
Study 28982667 — intervention group
Group type: EXPERIMENTAL
Intervention: Excretion of endogenous cholesterol
Number of subjects: 86
Study 28982667 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse cholesterol transport pathway
Number of subjects: 86
Study 28982765 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28982813 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherent patients
Number of subjects: 1000
Study 28982813 — intervention group
Group type: COMPARATOR
Intervention: Non-adherent patients
Number of subjects: 1000
Study 28982813 — intervention group
Group type: COMPARATOR
Intervention: Younger patients and men
Number of subjects: 1000
Study 28982813 — intervention group
Group type: COMPARATOR
Intervention: Patients viewing health status as dependent on external persons
Number of subjects: 1000
Study 28982813 — intervention group
Group type: COMPARATOR
Intervention: Patients viewing health status as determined by chance
Number of subjects: 1000
Study 28982813 — intervention group
Group type: COMPARATOR
Intervention: Overall anxiety levels
Number of subjects: 1000
Study 28982813 — intervention group
Group type: EXPERIMENTAL
Intervention: Married patients
Number of subjects: 1000
Study 28982814 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion regulation group therapy (ERGT)
Number of subjects: 95
Study 28982834 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 150
Study 28982834 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR levels
Number of subjects: 150
Study 28982839 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical evaluation subcohort (participants meeting three or more IGD criteria)
Number of subjects: 3000
Study 28982839 — intervention group
Group type: EXPERIMENTAL
Intervention: Representative subcohort (randomly selected 10% of the iCURE)
Number of subjects: 3000
Study 28982839 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments
Number of subjects: 3000
Study 28983018 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxetumomab pasudotox (30 µg/kg every other day for 6 doses)
Number of subjects: 55
Study 28983018 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxetumomab pasudotox (50 µg/kg for 10 doses)
Number of subjects: 55
Study 28983018 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxetumomab pasudotox (40 µg/kg for 10 doses)
Number of subjects: 55
Study 28983018 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxetumomab pasudotox (50 µg/kg × 6 doses)
Number of subjects: 55
Study 28983018 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxetumomab pasudotox
Number of subjects: 55
Study 28983166 — intervention group
Group type: EXPERIMENTAL
Intervention: Saudi nationals (SA nationals)
Number of subjects: 550
Study 28983166 — intervention group
Group type: COMPARATOR
Intervention: Expatriates
Number of subjects: 550
Study 28983166 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 550
Study 28983800 — intervention group
Group type: EXPERIMENTAL
Intervention: PKD1 non-truncating-type mutations at GPS-upstream domain
Number of subjects: 410
Study 28983800 — intervention group
Group type: EXPERIMENTAL
Intervention: PKD1 non-truncating-type mutations at transmembrane domain
Number of subjects: 410
Study 28983800 — intervention group
Group type: EXPERIMENTAL
Intervention: PKD1 non-truncating-type mutations at cytoplasmic C-terminal tail (CTT) domain
Number of subjects: 410
Study 28983800 — intervention group
Group type: EXPERIMENTAL
Intervention: PKD1 truncating-type mutations
Number of subjects: 410
Study 28983800 — intervention group
Group type: EXPERIMENTAL
Intervention: PKD1 3'-region truncating-type mutations
Number of subjects: 410
Study 28983800 — intervention group
Group type: EXPERIMENTAL
Intervention: PKD1 3'-region non-truncating-type mutations
Number of subjects: 410
Study 28983926 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride
Number of subjects: 2884
Study 28984053 — intervention group
Group type: EXPERIMENTAL
Intervention: AS04-HPV-16/18 vaccine
Number of subjects: 0
Study 28984179 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab beta
Number of subjects: 0
Study 28984179 — intervention group
Group type: COMPARATOR
Intervention: IM interferon beta-1a
Number of subjects: 0
Study 28984517 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) - either intensity modulated (IMRT) or 3D conformal (3DCRT), 54 Gy in 30 fractions
Number of subjects: 52
Study 28984517 — intervention group
Group type: COMPARATOR
Intervention: Historical control (GTR alone)
Number of subjects: 52
Study 28984517 — intervention group
Group type: COMPARATOR
Intervention: Historical control (GTR + RT)
Number of subjects: 52
Study 28984517 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT)
Number of subjects: 52
Study 28984909 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Number of subjects: 3693
Study 28984909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3693
Study 28985241 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Salt (HS) diet (18.0 g/day NaCl)
Number of subjects: 42
Study 28985241 — intervention group
Group type: COMPARATOR
Intervention: Low-Salt (LS) diet (3.0 g/day NaCl)
Number of subjects: 42
Study 28985241 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Salt + K+ (HS + K+) diet (18.0 g/day NaCl and 4.5 g/day KCl)
Number of subjects: 42
Study 28985589 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-factor PHQ-ADS model
Number of subjects: 182
Study 28985589 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ-ADS
Number of subjects: 182
Study 28985589 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress
Number of subjects: 182
Study 28986165 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body production (WBP) for glutamine
Number of subjects: 27
Study 28986165 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body production (WBP) for tau-methylhistidine
Number of subjects: 27
Study 28986165 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body production (WBP) for arginine
Number of subjects: 27
Study 28986165 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body production (WBP) for β-Hydroxy β-Methylbutyrate
Number of subjects: 27
Study 28986165 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearance of arginine
Number of subjects: 27
Study 28986165 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearance of glutamine
Number of subjects: 27
Study 28986165 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearance of leucine
Number of subjects: 27
Study 28986165 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearance of KIC
Number of subjects: 27
Study 28986165 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 27
Study 28986165 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak leg extension force
Number of subjects: 27
Study 28986266 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy (CE) with methylene blue 0.1%; n = 24
Number of subjects: 27
Study 28986266 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band Imaging (NBI); n = 26
Number of subjects: 27
Study 28986266 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy (CE)
Number of subjects: 27
Study 28986266 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band Imaging (NBI)
Number of subjects: 27
Study 28986266 — intervention group
Group type: EXPERIMENTAL
Intervention: High confidence diagnosis
Number of subjects: 27
Study 28986266 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of pit pattern I or II
Number of subjects: 27
Study 28986337 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular monitoring e-learning module
Number of subjects: 10000
Study 28986407 — intervention group
Group type: EXPERIMENTAL
Intervention: USPIO-enhanced MRI (ferumoxytol, 4 mg/kg)
Number of subjects: 14
Study 28986407 — intervention group
Group type: COMPARATOR
Intervention: USPIO-enhanced MRI
Number of subjects: 14
Study 28986415 — intervention group
Group type: EXPERIMENTAL
Intervention: Asleep DBS
Number of subjects: 69
Study 28986415 — intervention group
Group type: COMPARATOR
Intervention: Awake DBS
Number of subjects: 69
Study 28986471 — intervention group
Group type: EXPERIMENTAL
Intervention: AVICH score
Number of subjects: 325
Study 28986471 — intervention group
Group type: COMPARATOR
Intervention: ICH score
Number of subjects: 325
Study 28986471 — intervention group
Group type: COMPARATOR
Intervention: sSM grade
Number of subjects: 325
Study 28986471 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Rankin score (mRS)
Number of subjects: 325
Study 28986467 — intervention group
Group type: EXPERIMENTAL
Intervention: MDS-UPDRS Part I score in PD subjects
Number of subjects: 423
Study 28986467 — intervention group
Group type: COMPARATOR
Intervention: MDS-UPDRS Part I score in HC
Number of subjects: 423
Study 28986467 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal increase in NMS severity
Number of subjects: 423
Study 28986467 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline NMS score
Number of subjects: 423
Study 28986504 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (part of the TECOS trial)
Number of subjects: 1084
Study 28986852 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-CMV (fully synchronized pressure-controlled ventilation)
Number of subjects: 13
Study 28986852 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-SIMV (partially synchronized pressure-controlled ventilation)
Number of subjects: 13
Study 28986852 — intervention group
Group type: COMPARATOR
Intervention: PC-IMV (non-synchronized pressure-controlled ventilation using airway pressure release ventilation)
Number of subjects: 13
Study 28986931 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in VTI after 45° passive leg raising
Number of subjects: 40
Study 28986931 — intervention group
Group type: COMPARATOR
Intervention: Standardised anaesthesia, intravenous coloading, and prophylactic vasopressor treatment
Number of subjects: 40
Study 28987002 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline procollagen type I amino-terminal propeptide (P1NP)
Number of subjects: 973
Study 28987002 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline osteocalcin
Number of subjects: 973
Study 28987002 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline C-terminal telopeptide of type I collagen (CTX)
Number of subjects: 973
Study 28987002 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity during sports activities
Number of subjects: 973
Study 28987002 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean annual aBMD changes
Number of subjects: 973
Study 28988157 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe/major bleeding (measured by GUSTO, TIMI, ACUITY, and BARC scales)
Number of subjects: 25107
Study 28988157 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion requirement
Number of subjects: 25107
Study 28988157 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild/minor bleeding
Number of subjects: 25107
Study 28988157 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding definitions (GUSTO, TIMI, ACUITY, BARC)
Number of subjects: 25107
Study 28988183 — intervention group
Group type: EXPERIMENTAL
Intervention: Endo-CABG
Number of subjects: 150
Study 28988183 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention
Number of subjects: 150
Study 28988183 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteer group
Number of subjects: 150
Study 28988184 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty assessment in older patients undergoing emergency laparotomy
Number of subjects: 500
Study 28988198 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective ESD (S-ESD)
Number of subjects: 1765
Study 28988198 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal ESD (U-ESD)
Number of subjects: 1765
Study 28988198 — intervention group
Group type: COMPARATOR
Intervention: Wide-field endoscopic mucosal resection (WF-EMR)
Number of subjects: 1765
Study 28988211 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen-alone PHT
Number of subjects: 30034
Study 28988211 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen and progesterone PHT
Number of subjects: 30034
Study 28988211 — intervention group
Group type: COMPARATOR
Intervention: Younger age at menopause (<45 years)
Number of subjects: 30034
Study 28988211 — intervention group
Group type: COMPARATOR
Intervention: Menopausal age 45-49 years
Number of subjects: 30034
Study 28988211 — intervention group
Group type: COMPARATOR
Intervention: Menopausal age 50-54 years
Number of subjects: 30034
Study 28988211 — intervention group
Group type: COMPARATOR
Intervention: Menopausal age >54 years
Number of subjects: 30034
Study 28988331 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster with post-herpetic neuralgia
Number of subjects: 412
Study 28988331 — intervention group
Group type: COMPARATOR
Intervention: Herpes zoster without complications
Number of subjects: 412
Study 28988331 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall economic burden analysis
Number of subjects: 412
Study 28988934 — intervention group
Group type: EXPERIMENTAL
Intervention: WTX101 monotherapy at a starting dose of 15-60 mg/day for the first 4-8 weeks, with response-guided individualised dosing for the remaining weeks up to week 24.
Number of subjects: 28
Study 28988934 — intervention group
Group type: EXPERIMENTAL
Intervention: WTX101 monotherapy
Number of subjects: 28
Study 28989060 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation for HCC
Number of subjects: 1359
Study 28989060 — intervention group
Group type: EXPERIMENTAL
Intervention: Competing-risk regression analysis
Number of subjects: 1359
Study 28989060 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence analysis
Number of subjects: 1359
Study 28989706 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Dialectical Behaviour Therapy (DBT) for 12 months
Number of subjects: 54
Study 28990201 — intervention group
Group type: EXPERIMENTAL
Intervention: FIBTEM MCF values <8 mm
Number of subjects: 86
Study 28990201 — intervention group
Group type: EXPERIMENTAL
Intervention: FIBTEM MCF values >8 mm
Number of subjects: 86
Study 28990201 — intervention group
Group type: EXPERIMENTAL
Intervention: FIBTEM MCF values >10 mm
Number of subjects: 86
Study 28990201 — intervention group
Group type: COMPARATOR
Intervention: FIBTEM MCF
Number of subjects: 86
Study 28990589 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple anthropometric measures (weight and weight/length)
Number of subjects: 251
Study 28990589 — intervention group
Group type: EXPERIMENTAL
Intervention: Skinfold measures
Number of subjects: 251
Study 28991061 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Ropivacaine, initial volume 30 mL, adjusted by 2 mL based on previous subject's response
Number of subjects: 26
Study 28991112 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine administered over 15 minutes, dosage determined by the Dixon up-and-down method.
Number of subjects: 79
Study 28991404 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated trivalent influenza vaccine (TIV)
Number of subjects: 20
Study 28991876 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated Electronic-Health-Record providing feedback
Number of subjects: 1752
Study 28991900 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF-A in serum
Number of subjects: 20
Study 28991900 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF-C in plasma
Number of subjects: 20
Study 28991900 — intervention group
Group type: EXPERIMENTAL
Intervention: PLGF in plasma
Number of subjects: 20
Study 28991900 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF-A in plasma
Number of subjects: 20
Study 28991900 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian levels of VEGFs
Number of subjects: 20
Study 28991900 — intervention group
Group type: EXPERIMENTAL
Intervention: Single morning measurement of systemic VEGF levels
Number of subjects: 20
Study 28992094 — intervention group
Group type: EXPERIMENTAL
Intervention: In-center nocturnal hemodialysis (INHD), 7-8 hours/session, three times/week
Number of subjects: 67
Study 28992527 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD patients (n = 100)
Number of subjects: 100
Study 28992527 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 100)
Number of subjects: 100
Study 28993391 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Community of Care (ICoC)
Number of subjects: 250
Study 28993391 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 250
Study 28994184 — intervention group
Group type: EXPERIMENTAL
Intervention: High myopic cataract (HMC) lenses
Number of subjects: 0
Study 28994184 — intervention group
Group type: COMPARATOR
Intervention: Age-related cataract (ARC) lenses
Number of subjects: 0
Study 28994660 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) 25 mg, once daily
Number of subjects: 20
Study 28994660 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 20
Study 29016235 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine support group intervention using encrypted tablet-based videoconferencing.
Number of subjects: 0
Study 29016235 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine support group intervention
Number of subjects: 0
Study 29016504 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacuation proctography
Number of subjects: 131
Study 29016504 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 131
Study 29016504 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal ultrasonography
Number of subjects: 131
Study 29016504 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovaginal ultrasonography
Number of subjects: 131
Study 29016504 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal ultrasonography and Endovaginal ultrasonography
Number of subjects: 131
Study 29016506 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive practices (no intercourse, protected intercourse, unprotected intercourse, or tried to conceive) classified based on the preceding year.
Number of subjects: 710
Study 29016506 — intervention group
Group type: EXPERIMENTAL
Intervention: Conception rates across follow-up.
Number of subjects: 710
Study 29016506 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, marital status, and preoperative importance of future pregnancy as factors influencing early conception.
Number of subjects: 710
Study 29016755 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 0
Study 29016755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioversion
Number of subjects: 0
Study 29016813 — intervention group
Group type: EXPERIMENTAL
Intervention: AtriClip device for epicardial left atrial appendage (LAA) occlusion
Number of subjects: 291
Study 29016998 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 140 mg/day
Number of subjects: 152
Study 29016998 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 100 mg/day
Number of subjects: 152
Study 29016998 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 152
Study 29017455 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil adjusted to approximately 6.5 ng/mL before head fixation
Number of subjects: 50
Study 29017455 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hemodynamic values recorded before head fixation
Number of subjects: 50
Study 29017461 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge after TF-TAVI
Number of subjects: 0
Study 29017461 — intervention group
Group type: COMPARATOR
Intervention: Late discharge after TF-TAVI
Number of subjects: 0
Study 29017466 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli isolates from patients with uUTI
Number of subjects: 485
Study 29017466 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli isolates from patients with cUTI
Number of subjects: 485